Identifying aggressive versus non-aggressive prostate cancer using genomic markers
Official title: Genomic marker to distinguish aggressive and indolent prostate cancer
Funded at Biomarker Corporation · NIH-10820859 · Data updated 2026-11-12
This study is looking at a special marker in prostate cancer that can help doctors tell if a tumor is aggressive or not, so they can better decide if men with low-risk prostate cancer need treatment right away or if they can just be watched closely.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biomarker Corporation NIH-funded |
| Lab location | 1 site (South San Francisco, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $404,201 |
| NIH project number | 1R43CA287601-01 |
| Project ID | NIH-10820859 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with low-risk prostate cancer who are considering Active Surveillance.
✕Less likely to help
Patients with aggressive prostate cancer or those who have already undergone treatment may not benefit from this research.
What this research studies
This research investigates a genomic marker called GEMCaP that helps distinguish between aggressive and indolent forms of prostate cancer. By analyzing tumor DNA from biopsies, the study aims to improve treatment decisions for men diagnosed with prostate cancer, particularly those classified as low-risk. The goal is to identify which tumors may require immediate treatment and which can be safely monitored through Active Surveillance. This approach could lead to more personalized and effective management of prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to better treatment decisions for prostate cancer patients, reducing unnecessary surgeries and associated side effects.
How similar studies have gone: Previous research has shown promise in using genomic markers for cancer diagnosis, suggesting that this approach could be effective.
Where this research is happening
-
Biomarker Corporation
South San Francisco, United States Active
Researchers
- Principal investigator: Davis, Randall — Biomarker Corporation
- Study coordinator: Davis, Randall
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.